Research progress on molecular typing detection of endometrial cancer
SHI Minjie1 XIE Baoguo2
1.Hainan Medical University, Hainan Province, Haikou 570102, China;
2.Department of Reproductive Medicine, the First Affiliated Hospital of Hainan Medical University, Hainan Province, Haikou 570102, China
Abstract：Endometrial cancer (EC) is a serious threat to women’s health. In recent years, with the influence of many factors such as economy and environment, EC is gradually developing towards higher incidence and younger trend, and has surpassed cervical cancer and ovarian cancer to become gynecological malignancy with the highest incidence rate in some developed European countries. At present, clinical studies on tumor have entered the age of molecular typing, which is closely related to the rapid development of molecular biological technology research. This paper reviews the challenges in the current classification system of endometrial carcinoma, the development of new molecular techniques to define and predict different molecular subtypes, and the potential applications of molecular typing.
[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Bokhman JV. Two pathogenetic types of endometrial carcinoma [J]. Gynecol Oncol，1983，15（1）：10-17.
[3] Murali R，Soslow RA，Weigelt B. Classification of endometrial carcinoma：more than two types [J]. Lancet Oncol，2014， 15（7）：e268-e278.
[4] Setiawan VW，Yang HP，Pike MC，et al. Type Ⅰ and Ⅱ endometrial cancers：have they different risk factors？[J]. J Clin Oncol，2013，31（20）：2607-2618.
[5] Kandoth C，Schultz N，Cherniack AD，et al. Integrated genomic characterization of endometrial carcinoma [J]. Nature，2013，497（7447）：67-73.
[6] 段亚伟，张丽华.子宫内膜癌TCGA分子检测分型的进展[J].临床与实验病理学杂志，2020，36（3）：320-322.
[7] Talhouk A，Mcconechy MK，Leung S，et al. A clinically applicable molecular-based classification for endometrial cancers [J]. Br J Cancer，2015，113（2）：299-310.
[8] Stelloo E，Nout RA，Osse EM，et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts [J]. Clin Cancer Res，2016，22（16）：4215-4224.
[9] Concin N，Creutzberg CL，Vergote I，et al. ESGO/ESTRO/ ESP Guidelines for the management of patients with endometrial carcinoma [J]. Virchows Arch，2021，478（2）：153- 190.
[10] Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients：an overview of the literature from 1982 to 2008 [J]. Health Qual Life Outcomes，2009， 7：102.
[11] Soslow RA. Endometrial carcinomas with ambiguous features [J]. Semin Diagn Pathol，2010，27（4）：261-273.
[12] Hussein YR，Soslow RA. Molecular insights into the classification of high-grade endometrial carcinoma [J]. Pathology，2018，50（2）：151-161.
[13] Bellone S，Bignotti E，Lonardi S，et al. Polymerase epsilon（POLE）ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro [J]. Gynecol Oncol，2017，144（1）：146-152.
[14] Van Gool IC，Rarner E，Osse EM，et al. Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers：Sensitivity to Radiotherapy，Chemotherapy，and Nucleoside Analogues [J]. Clin Cancer Res，2018，24（13）：3197-3203.
[15] Espinosa I，Lee CH，Dangelo E，et al. Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis [J]. Am J Surg Pathol，2017，41（8）：1121-1128.
[16] Lynch HT，Snyder CL，Shaw TG，et al. Milestones of Lynch syndrome：1895-2015 [J]. Nat Rev Cancer，2015，15（3）：181-194.
[17] Biller LH，Syngal S，Yurfelun MB. Recent advances in Lynch syndrome [J]. Fam Cancer，2019，18（2）：211-219.
[18] Ferreira AM，Tuominen I，van Dijk-Bos K，et al. High frequency of RPL22 mutations in microsatellite-unstable colorectal and endometrial tumors [J]. Hum Mutat，2014，35（12）：1442-1445.
[19] Talhouk A，Hoang LN，Mcconechy MK，et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy：Earlier prognostic information to guide treatment [J]. Gynecol Oncol，2016，143（1）：46-53.
[20] Talhouk A，Mcconechy MK，Leung S，et al. Confirmation of ProMisE：A simple，genomics-based clinical classifier for endometrial cancer [J]. Cancer，2017，123（5）：802-813.
[21] Kommoss S，Mcconechy MK，Kommoss F，et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series [J]. Ann Oncol，2018，29（5）：1180-1188.
[22] Raffone A，Travaglino A，Mascolo M，et al. TCGA molecular groups of endometrial cancer：Pooled data about prognosis [J]. Gynecol Oncol，2019，155（2）：374-383.
[23] Stelloo E，Bosse T，Nout RA，et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer：a TransPORTEC initiative [J]. Mod Pathol，2015，28（6）：836-844.
[24] Murali R，Delair DF，Bean SM，et al. Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer [J]. J Natl Compr Canc Netw，2018，16（2）：201-209.
[25] Santoro A，Piermattei A，Inzani F，et al. Frozen section accurately allows pathological characterization of endometrial cancer in patients with a preoperative ambiguous or inconclusive diagnoses：our experience [J]. BMC Cancer，2019， 19（1）：1096.
[26] Raffone A，Travaglino A，Mascolo M，et al. TCGA molecular groups of endometrial cancer：Pooled data about prognosis [J]. Gynecol Oncol，2019，155（2）：374-383.
[27] Mcalpine J，Leon-Castillo A，Bosse T. The rise of a novel classification system for endometrial carcinoma；integration of molecular subclasses [J]. J Pathol，2018，244（5）：538- 549.
[28] Concin N，Creutzberg CL，Vergote I，et al. ESGO/ESTRO/ ESP Guidelines for the management of patients with endometrial carcinoma [J]. Virchows Arch，2021，478（2）：153-190.
[29] Travaglino A，Raffone A，Stradella C，et al. Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups [J]. Arch Gynecol Obstet，2020，301（6）：1355-1363.
京公网安备 11010502046598号